OCTAGON CAPITAL ADVISORS
Octagon Capital invests in public and private healthcare companies globally. Octagon Capital focuses on strategic long-term investments and strive to work with our portfolio management teams as partners.
OCTAGON CAPITAL ADVISORS
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Font Awesome Apache Global Site Tag
Similar Organizations
1315 Capital
1315 Capital provides expansion and growth capital to commercial stage pharmaceuticals, medical technologies, and healthcare services.
Rex Health Ventures
Rex Health Ventures is the corporate venture arm of UNC Healthcare and invests in cutting edge healthcare companies.
Venrock
Venrock is a venture capital firm investing in technology and healthcare companies.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-25 | Aktis Oncology | Octagon Capital Advisors investment in Series A - Aktis Oncology | 84 M USD |
| 2022-08-16 | Bluejay Therapeutics | Octagon Capital Advisors investment in Series B - Bluejay Therapeutics | 41 M USD |
| 2022-02-15 | ArriVent Biopharma | Octagon Capital Advisors investment in Series A - ArriVent Biopharma | 69 M USD |
| 2021-12-14 | AnHeart Therapeutics | Octagon Capital Advisors investment in Series B - AnHeart Therapeutics | 61 M USD |
| 2021-11-24 | Allorion Therapeutics | Octagon Capital Advisors investment in Series A - Allorion Therapeutics | 40 M USD |
| 2021-11-05 | Edge Medical Robotics | Octagon Capital Advisors investment in Series C - Edge Medical Robotics | 200 M USD |
| 2021-09-13 | Alebund Pharmaceuticals | Octagon Capital Advisors investment in Series B - Alebund Pharmaceuticals | 54.5 M USD |
| 2021-06-30 | ArriVent Biopharma | Octagon Capital Advisors investment in Series A - ArriVent Biopharma | 81 M USD |
| 2021-05-26 | NiKang Therapeutics | Octagon Capital Advisors investment in Series C - NiKang Therapeutics | 200 M USD |
| 2021-05-19 | Numab | Octagon Capital Advisors investment in Series C - Numab | 100 M CHF |